Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men
| Autor: | Aditi Sapre, Klaus von Bergmann, Dieter Lütjohann, Patrice H. Gibbons, Thomas Musliner, William Taggart, Thomas Sudhop, Michael Reber, Diane Tribble |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Simvastatin Hypercholesterolemia QD415-436 Pharmacology Placebo Biochemistry Excretion Young Adult chemistry.chemical_compound Endocrinology Double-Blind Method Ezetimibe polycyclic compounds medicine Humans cholesterol absorption and synthesis Cholesterol business.industry Anticholesteremic Agents nutritional and metabolic diseases Cell Biology Middle Aged Crossover study Sterol Drug Combinations chemistry Azetidines lipids (amino acids peptides and proteins) Patient-Oriented and Epidemiological Research business cholesterol balance ezetimibe simvastatin combination medicine.drug |
| Zdroj: | Journal of Lipid Research, Vol 50, Iss 10, Pp 2117-2123 (2009) |
| ISSN: | 0022-2275 |
| DOI: | 10.1194/jlr.p900004-jlr200 |
| Popis: | This study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or cholesterol synthesis or coadministration of both agents. This was a randomized, double blind, placebo-controlled, four-period crossover study to evaluate the effects of coadministering 10 mg ezetimibe with 20 mg simvastatin (ezetimibe/simvastatin) on cholesterol absorption and synthesis relative to either drug alone or placebo in 41 subjects. Each treatment period lasted 7 weeks. Ezetimibe and ezetimibe/simvastatin decreased fractional cholesterol absorption by 65% and 59%, respectively (P < 0.001 for both relative to placebo). Simvastatin did not significantly affect cholesterol absorption. Ezetimibe and ezetimibe/simvastatin increased fecal sterol excretion (corrected for dietary cholesterol), which also represents net steady state cholesterol synthesis, by 109% and 79%, respectively (P < 0.001). Ezetimibe, simvastatin, and ezetimibe/simvastatin decreased plasma LDL-cholesterol by 20, 38, and 55%, respectively. The coadministered therapy was well tolerated. The decreases in net cholesterol synthesis and increased fecal sterol excretion yielded nearly additive reductions in LDL-cholesterol for the coadministration of ezetimibe and simvastatin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|